Results 11 to 20 of about 410 (175)

Temporal trends in evidence supporting therapeutic interventions in heart failure and other European Society of Cardiology guidelines. [PDF]

open access: yesESC Heart Fail, 2023
Abstract Aims This study aimed to determine whether any change occurred over time in level of evidence (LoE) of therapeutic interventions supporting heart failure (HF) and other European Society of Cardiology guideline recommendations. Methods and results We selected topics with at least three documents released between 2008 and April 2022.
Canepa M   +7 more
europepmc   +2 more sources

Association between heart failure quality of care and mortality: a population-based cohort study using nationwide registries. [PDF]

open access: yesEur J Heart Fail, 2022
Hospital performance and outcomes according to the 2021 European Society of Cardiology (ESC) quality indicators for heart failure (HF). ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; HFrEF, heart failure ...
Batra G   +8 more
europepmc   +2 more sources

Interaction of heart failure and stroke: A clinical consensus statement of the ESC Council on Stroke, the Heart Failure Association (HFA) and the ESC Working Group on Thrombosis

open access: yesEuropean Journal of Heart Failure, Volume 25, Issue 12, Page 2107-2129, December 2023., 2023
ABSTRACT Heart failure (HF) is a major disease in our society that often presents with multiple comorbidities with mutual interaction and aggravation. The comorbidity of HF and stroke is a high risk condition that requires particular attention to ensure early detection of complications, efficient diagnostic workup, close monitoring, and consequent ...
Wolfram Doehner   +13 more
wiley   +1 more source

A drug utilization study of thiocolchicoside‐containing medicinal products for systemic use in France and Italy: A cross‐sectional electronic medical records database study

open access: yesPharmacoepidemiology and Drug Safety, Volume 32, Issue 10, Page 1093-1102, October 2023., 2023
Abstract Purpose The risk minimization measures (RMM) for systemic use of thiocolchicoside (TCC) was implemented across Europe during 2014–2016. RMM included restriction of use in age <16 years, maximum dose and duration, chronic conditions, contraindication in pregnancy, lactation or in women of childbearing potential [WOCBP] without appropriate ...
Annie Druet‐Cabanac   +6 more
wiley   +1 more source

Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in‐hospital and long‐term outcomes – from the ESC‐HFA EORP Heart Failure Long‐Term Registry

open access: yesEuropean Journal of Heart Failure, Volume 25, Issue 9, Page 1571-1583, September 2023., 2023
In patients with acute heart failure, 20% had hyponatreamia at hospital admission, which was associated with more advanced heart failure and normalized in half of patients during hospitalization. Admission hyponatreamia (possibly dilutional), especially persisting during hospitalization, was associated with worse in‐hospital and post‐dicharge prognosis.
Agnieszka Kapłon‐Cieślicka   +693 more
wiley   +1 more source

Patient profiles in heart failure with reduced ejection fraction: Prevalence, characteristics, treatments and outcomes in a real‐world heart failure population

open access: yesEuropean Journal of Heart Failure, Volume 25, Issue 8, Page 1246-1253, August 2023., 2023
Clinical variables combined to generate profiles and their representation in a cohort of 47 241 patients with heart failure with reduced ejection fraction (HFrEF). AF, atrial fibrillation; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HR, heart rate; HyperK, hyperkalaemia; sBP, systolic blood pressure.
Francesca Musella   +11 more
wiley   +1 more source

Eligibility for vericiguat in a real‐world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry

open access: yesEuropean Journal of Heart Failure, Volume 25, Issue 8, Page 1418-1428, August 2023., 2023
Proportion and outcomes of patients eligible for vericiguat according to trial, guideline, and label criteria in patients with chronic HFrEF. ACS, acute coronary syndrome; CV, cardiovascular; eGFR, estimated glomerular filtration rate; GDMT, guideline‐directed medical therapy; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ...
Ngoc V. Nguyen   +11 more
wiley   +1 more source

Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

open access: yesEuropean Journal of Heart Failure, Volume 25, Issue 7, Page 936-955, July 2023., 2023
Abstract Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation of various combinations of cardiovascular, metabolic, pulmonary, renal, and geriatric conditions.
Stefan D. Anker   +38 more
wiley   +1 more source

Ceramide and phosphatidylcholine lipids-based risk score predicts major cardiovascular outcomes in patients with heart failure. [PDF]

open access: yesEur J Clin Invest
Abstract Background Ceramide and phosphatidylcholine lipids‐based risk score (CERT2) has shown a strong prognostic value in predicting cardiovascular (CV) events in patients with ischemic heart disease. This study aimed to investigate the prognostic value of CERT2 risk score in patients with heart failure (HF).
Witoslawska A   +12 more
europepmc   +2 more sources

Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long‐Term Registry

open access: yesEuropean Journal of Heart Failure, Volume 25, Issue 7, Page 1049-1060, July 2023., 2023
Aortic valve disease in patients with heart failure and reduced, mildly reduced and preserved ejection fraction: The ESC Heart Failure Long‐Term Registry. AR, aortic regurgitation; AS, aortic stenosis; AVD, aortic valve disease; BMI, body mass index; CI, confidence interval; EF, ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ...
Bahira Shahim   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy